Why the study?
Do different antithrombotic regimens (aspirin, warfarin, or combination) improve platelet aggregate ratio in patients after acute myocardial infarction?
Do different antithrombotic regimens (aspirin, warfarin, or combination) improve platelet aggregate ratio in patients after acute myocardial infarction?
Different antithrombotic regimens post-MI show varying effects on platelet aggregation, with some patients exhibiting aspirin non-responsiveness.
Antithrombotics reduce platelet aggregation post-MI; confirms regimen-specific effects and supports outcome trials on clinical benefit.
Platelet aggregate ratio (PAR) was measured according to the method of Wu & Hoak in 143 patients after acute myocardial infarction (AMI) and in 54 controls. A PAR < 1 expresses the presence of platelet aggregates. The patients were randomized to aspirin 160 mg/d, or warfarin, or aspirin 75 mg/d + warfarin. In patients on aspirin, PAR was measured 24 h after aspirin intake, and in 76 patients also 2 h after aspirin. The median PAR in patients on warfarin was 0.85, on warfarin + aspirin 0.91 and on aspirin alone 0.94, all significantly lower than the median PAR of 0.97 in the controls. In 14 patients on aspirin the PARs were below a cut-off point of 0.82 (secondary aspirin non-responders). PAR increase significantly 2 h after aspirin intake. In two patients, however, PAR remained low (primary aspirin non-responders). It is concluded that some patients do not seem to respond to aspirin, the clinical implication of which has yet to be determined.
No takes yet. Share an insight, caveat, or question.
Hurlen et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: